Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,033 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study.
Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Song Y, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M; Uro-Oncology Group in Kyushu (UROKYU). Furubayashi N, et al. Among authors: koga t. Anticancer Res. 2024 Jul;44(7):3025-3032. doi: 10.21873/anticanres.17115. Anticancer Res. 2024. PMID: 38925809
Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status.
Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Song Y, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M; Uro-Oncology Group in Kyushu (UROKYU). Furubayashi N, et al. Among authors: koga t. Anticancer Res. 2024 Aug;44(8):3409-3417. doi: 10.21873/anticanres.17161. Anticancer Res. 2024. PMID: 39060060
2,033 results